Solventum (NYSE:SOLV) Raised to Hold at BMO Capital Markets

Solventum (NYSE:SOLV) was upgraded by research analysts at BMO Capital Markets to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

SOLV has been the subject of several other research reports. Piper Sandler cut their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings downgraded shares of Solventum from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, June 26th. BTIG Research reiterated a “buy” rating and set a $89.00 price target on shares of Solventum in a research report on Wednesday, May 6th. Finally, UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Thursday, May 14th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and a consensus target price of $83.50.

Solventum Price Performance

Solventum stock opened at $76.02 on Wednesday. The stock’s fifty day moving average price is $76.04 and its two-hundred day moving average price is $74.30. Solventum has a one year low of $62.38 and a one year high of $88.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a market cap of $13.17 billion, a PE ratio of 9.32, a price-to-earnings-growth ratio of 1.16 and a beta of 0.66.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Assetmark Inc. lifted its stake in shares of Solventum by 21.4% in the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after acquiring an additional 128 shares during the last quarter. Hilltop National Bank grew its position in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares during the last quarter. Allworth Financial LP grew its position in Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after acquiring an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in Solventum by 0.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares in the last quarter. Finally, BOKF NA increased its holdings in Solventum by 6.9% in the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.